AR126578A1 - Anticuerpos anti-ccr8 - Google Patents
Anticuerpos anti-ccr8Info
- Publication number
- AR126578A1 AR126578A1 ARP220101985A ARP220101985A AR126578A1 AR 126578 A1 AR126578 A1 AR 126578A1 AR P220101985 A ARP220101985 A AR P220101985A AR P220101985 A ARP220101985 A AR P220101985A AR 126578 A1 AR126578 A1 AR 126578A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- cdr
- antibody
- ccr8
- set forth
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un anticuerpo anti-CCR8 caracterizado porque comprende (i) una cadena VH que comprende tres CDR; y (ii) una cadena VL que comprende tres CDR, en donde: la VH CDR#1 es GFIFSNAVMY (SEQ ID Nº 1); la VH CDR#2 es RIKTKFNNYATYYADAVKG (SEQ ID Nº 2); la VH CDR#3 es GDRNKPFAY (SEQ ID Nº 3); la VL CDR#1 es RASTSVITLLH (SEQ ID Nº 4); la VL CDR#2 es GASNLES (SEQ ID Nº 5); y la VL CDR#3 es QQSWNDPYT (SEQ ID Nº 6). Reivindicación 2: El anticuerpo anti-CCR8 de la reivindicación 1, caracterizado porque el anticuerpo comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos que se establece como la SEQ ID Nº 7 y una región variable de cadena liviana que comprende la secuencia de aminoácidos que se establece como la SEQ ID Nº 8. Reivindicación 3: El anticuerpo anti-CCR8 de la reivindicación 1, caracterizado porque el anticuerpo comprende una cadena pesada que comprende la secuencia de aminoácidos que se establece como la SEQ ID Nº 9 y una cadena liviana que comprende la secuencia de aminoácidos que se establece como la SEQ ID Nº 10. Reivindicación 4: El anticuerpo anti-CCR8 de acuerdo con la reivindicación 3, caracterizado porque el anticuerpo está afucosilado. Reivindicación 5: Una composición caracterizada porque comprende una pluralidad de los anticuerpos anti-CCR8 de la reivindicación 1. Reivindicación 7: El anticuerpo anti-CCR8 de la reivindicación 1, caracterizado porque es una IgG. Reivindicación 16: Un método para tratar tumores sólidos, caracterizado porque el método comprende administrar la composición de la reivindicación 5 a un paciente que lo necesite.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226118P | 2021-07-27 | 2021-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126578A1 true AR126578A1 (es) | 2023-10-25 |
Family
ID=82898810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101985A AR126578A1 (es) | 2021-07-27 | 2022-07-27 | Anticuerpos anti-ccr8 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11639393B2 (es) |
| EP (2) | EP4214240B1 (es) |
| JP (1) | JP2023018678A (es) |
| KR (1) | KR20240067052A (es) |
| CN (1) | CN117425677A (es) |
| AR (1) | AR126578A1 (es) |
| AU (1) | AU2022317803A1 (es) |
| BR (1) | BR112023024837A2 (es) |
| CA (1) | CA3220121A1 (es) |
| CO (1) | CO2023015915A2 (es) |
| DK (1) | DK4214240T3 (es) |
| FI (1) | FI4214240T3 (es) |
| IL (1) | IL307533A (es) |
| LT (1) | LT4214240T (es) |
| MX (1) | MX2023014154A (es) |
| PL (1) | PL4214240T3 (es) |
| PT (1) | PT4214240T (es) |
| RS (1) | RS66234B1 (es) |
| SM (1) | SMT202400483T1 (es) |
| TW (1) | TW202321304A (es) |
| WO (1) | WO2023010054A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20231067A1 (es) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
| WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| EP3458473B8 (en) | 2016-05-16 | 2022-08-17 | Checkmab S.R.L. | Markers selectively deregulated in tumor-infiltrating regulatory t cells. |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| PT3616720T (pt) | 2017-03-29 | 2021-03-11 | Shionogi & Co | Composição medicinal para tratamento de cancro |
| BR112021011431A2 (pt) | 2018-12-27 | 2021-11-23 | Univ Osaka | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit |
| WO2021142002A1 (en) | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| PE20231067A1 (es) * | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
| EP4114862A4 (en) | 2020-03-05 | 2024-07-03 | Memorial Sloan Kettering Cancer Center | Anti-ccr8 agents |
| EP4126950A1 (en) | 2020-03-23 | 2023-02-08 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| CA3190879A1 (en) | 2020-08-28 | 2022-03-03 | Shuang LU | Ccr8 antibody and application thereof |
| US20230416382A1 (en) | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| WO2022078277A1 (en) | 2020-10-16 | 2022-04-21 | Lanova Medicines Limited Company | Anti-ccr8 monoclonal antibodies and uses thereof |
| US20240052044A1 (en) | 2020-12-24 | 2024-02-15 | Vib Vzw | Non-blocking human ccr8 binders |
| US20240076391A1 (en) | 2020-12-24 | 2024-03-07 | Oncurious Nv | Human ccr8 binders |
-
2022
- 2022-07-27 US US17/815,505 patent/US11639393B2/en active Active
- 2022-07-27 RS RS20241306A patent/RS66234B1/sr unknown
- 2022-07-27 FI FIEP22754752.8T patent/FI4214240T3/fi active
- 2022-07-27 JP JP2022119632A patent/JP2023018678A/ja active Pending
- 2022-07-27 MX MX2023014154A patent/MX2023014154A/es unknown
- 2022-07-27 LT LTEPPCT/US2022/074214T patent/LT4214240T/lt unknown
- 2022-07-27 DK DK22754752.8T patent/DK4214240T3/da active
- 2022-07-27 PT PT227547528T patent/PT4214240T/pt unknown
- 2022-07-27 WO PCT/US2022/074214 patent/WO2023010054A1/en active Application Filing
- 2022-07-27 EP EP22754752.8A patent/EP4214240B1/en active Active
- 2022-07-27 IL IL307533A patent/IL307533A/en unknown
- 2022-07-27 AR ARP220101985A patent/AR126578A1/es unknown
- 2022-07-27 CN CN202280040102.9A patent/CN117425677A/zh active Pending
- 2022-07-27 BR BR112023024837A patent/BR112023024837A2/pt unknown
- 2022-07-27 PL PL22754752.8T patent/PL4214240T3/pl unknown
- 2022-07-27 TW TW111128155A patent/TW202321304A/zh unknown
- 2022-07-27 CA CA3220121A patent/CA3220121A1/en active Pending
- 2022-07-27 SM SM20240483T patent/SMT202400483T1/it unknown
- 2022-07-27 EP EP24198142.2A patent/EP4491635A2/en active Pending
- 2022-07-27 AU AU2022317803A patent/AU2022317803A1/en active Pending
- 2022-07-27 KR KR1020237041895A patent/KR20240067052A/ko not_active Application Discontinuation
-
2023
- 2023-11-22 CO CONC2023/0015915A patent/CO2023015915A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT4214240T (pt) | 2024-11-25 |
| FI4214240T3 (fi) | 2024-11-14 |
| PL4214240T3 (pl) | 2025-01-07 |
| AU2022317803A1 (en) | 2023-10-26 |
| SMT202400483T1 (it) | 2025-01-14 |
| EP4491635A2 (en) | 2025-01-15 |
| US11639393B2 (en) | 2023-05-02 |
| CO2023015915A2 (es) | 2023-12-11 |
| EP4214240A1 (en) | 2023-07-26 |
| DK4214240T3 (da) | 2024-11-18 |
| IL307533A (en) | 2023-12-01 |
| BR112023024837A2 (pt) | 2024-02-20 |
| MX2023014154A (es) | 2024-05-14 |
| LT4214240T (lt) | 2024-11-25 |
| RS66234B1 (sr) | 2024-12-31 |
| JP2023018678A (ja) | 2023-02-08 |
| TW202321304A (zh) | 2023-06-01 |
| CA3220121A1 (en) | 2023-02-02 |
| US20230048553A1 (en) | 2023-02-16 |
| CN117425677A (zh) | 2024-01-19 |
| EP4214240B1 (en) | 2024-10-09 |
| KR20240067052A (ko) | 2024-05-16 |
| WO2023010054A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126578A1 (es) | Anticuerpos anti-ccr8 | |
| AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| PE20211867A1 (es) | Anticuerpos biespecificos y su uso | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR109533A2 (es) | Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios | |
| AR075790A2 (es) | Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural) | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| PE20121494A1 (es) | Anticuerpos anti notch-1 | |
| JOP20210013A1 (ar) | تركيبات جسم مضاد fcrn | |
| AR125473A1 (es) | Conjugados de anticuerpo anti-c-met y fármaco | |
| MX2024009976A (es) | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. | |
| CO2022004743A2 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| PE20180498A1 (es) | Inmunoglobulinas conjugadas en cys80 | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| AR120430A1 (es) | Células car-t dirigidas a epha3 para el tratamiento de tumores | |
| BR112022007349A2 (pt) | Homodímero de quinureninase, método para produzir um homodímero de quinureninase peguilado, formulação farmacêutica e método para tratar um sujeito tendo um tumor | |
| AR130144A1 (es) | Proteínas de unión a nkg2d, cd16 y ceacam5 | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR127270A1 (es) | Formulación de anticuerpos anti-cd47 |